Holen Sie sich die Stockscreener-App
16.49
0.43%
0.07
Handel nachbörslich:
16.57
0.08
+0.49%
Schlusskurs vom Vortag:
$16.42
Offen:
$16.4
24-Stunden-Volumen:
286.07K
Relative Volume:
0.53
Marktkapitalisierung:
$1.04B
Einnahmen:
$202.09M
Nettoeinkommen (Verlust:
$-61.69M
KGV:
-14.09
EPS:
-1.17
Netto-Cashflow:
$-35.64M
1W Leistung:
-1.20%
1M Leistung:
+0.92%
6M Leistung:
+23.98%
1J Leistung:
+107.94%
1-Tages-Spanne:
$16.27
$16.68
1-Wochen-Bereich:
$15.95
$16.98
52-Wochen-Spanne:
$7.74
$17.82
Evolus Inc Stock (EOLS) Company Profile
Firmenname
Evolus Inc
Sektor
Telefon
(949) 284-4555
Adresse
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-01-29 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-06-23 | Eingeleitet | Needham | Buy |
| 2022-05-12 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-01-20 | Hochstufung | Truist | Hold → Buy |
| 2021-05-06 | Hochstufung | Mizuho | Neutral → Buy |
| 2021-04-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-02-24 | Herabstufung | Truist | Buy → Hold |
| 2020-07-07 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-02-06 | Fortgesetzt | Mizuho | Buy |
| 2019-11-26 | Eingeleitet | SVB Leerink | Outperform |
| 2019-09-05 | Fortgesetzt | Mizuho | Buy |
| 2019-06-28 | Eingeleitet | Wells Fargo | Market Perform |
| 2019-06-11 | Eingeleitet | Barclays | Underweight |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2019-02-14 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-01-29 | Eingeleitet | Stifel | Buy |
Alle ansehen
Evolus Inc Aktie (EOLS) Neueste Nachrichten
Injections For Your Frown Lines Cost Just $49, Thanks To This Membership Club - The Zoe Report
Prescription Hair Loss and Hair Removal Drugs Market Projected To Witness Substantial Growth, 2024-2031: - EIN News
Evolus (NASDAQ:EOLS) Earns "Buy" Rating from HC Wainwright - MarketBeat
Evolus to Participate in Stifel 2024 Healthcare Conference - The Bakersfield Californian
Evolus, Inc. (NASDAQ:EOLS) Shares Purchased by Rice Hall James & Associates LLC - MarketBeat
Objective long/short (EOLS) Report - Stock Traders Daily
Evolus, Inc. Announces EU Approval of Estyme Injectable Hyaluronic Acid Gels Under New Medical Device Regulation - Marketscreener.com
Evolus Gets EU Approval for Treatment of Wrinkles - MarketWatch
Evolus gains EU certification for new dermal filler products - Investing.com
Evolus gains EU certification for new dermal filler products By Investing.com - Investing.com UK
Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation - StockTitan
Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know - MSN
Evolus (EOLS) Scheduled to Post Quarterly Earnings on Wednesday - MarketBeat
Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers - StockTitan
Semanteon Capital Management LP Purchases Shares of 56,313 Evolus, Inc. (NASDAQ:EOLS) - MarketBeat
Evolus Inc (EOLS) Trading 3.55% Higher on Oct 25 - GuruFocus.com
Evolus to Report Third Quarter Financial Results on November 6, 2024 - Business Wire
First Week of December 20th Options Trading For Evolus (EOLS) - Nasdaq
Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet? - Simply Wall St
When the Price of (EOLS) Talks, People Listen - Stock Traders Daily
Evolus (NASDAQ:EOLS) Shares Down 6.2%Here's Why - MarketBeat
Evolus Inc (EOLS) Stock Price Down 4.81% on Oct 17 - GuruFocus.com
Evolus Inc (EOLS) receives an Overweight rating from Barclays - Knox Daily
SG Americas Securities LLC Makes New $623,000 Investment in Evolus, Inc. (NASDAQ:EOLS) - MarketBeat
Evolus (NASDAQ:EOLS) Hits New 1-Year HighTime to Buy? - MarketBeat
Evolus stock soars to 52-week high, hits $17.75 - Investing.com India
Evolus stock soars to 52-week high, hits $17.75 By Investing.com - Investing.com UK
Evolus Inc (EOLS) Trading 3.55% Higher on Oct 14 - GuruFocus.com
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 12, 2024 - BioSpace
Evolus Inc (EOLS) shows promising results - US Post News
(EOLS) Trading Report - Stock Traders Daily
Evolus' (NASDAQ:EOLS) investors will be pleased with their solid 119% return over the last three years - Yahoo Finance
Evolus Inc (EOLS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements - Yahoo Finance
Evolus, Inc. (NASDAQ:EOLS) Shares Sold by Millennium Management LLC - MarketBeat
Healthcare of Ontario Pension Plan Trust Fund Invests $1.33 Million in Evolus, Inc. (NASDAQ:EOLS) - MarketBeat
Q3 2024 Earnings Estimate for Evolus, Inc. Issued By HC Wainwright (NASDAQ:EOLS) - MarketBeat
Evolus (NASDAQ:EOLS) Trading Down 3.4%Here's Why - MarketBeat
Q4 2024 Earnings Forecast for Evolus, Inc. Issued By HC Wainwright (NASDAQ:EOLS) - MarketBeat
Evolus Bus Event - StyleBlueprint
Evolus shares hold Buy rating amid market gains By Investing.com - Investing.com Australia
Evolus shares hold Buy rating amid market gains - Investing.com
A Closer Look at 5 Analyst Recommendations For Evolus - Benzinga
HC Wainwright Reaffirms Buy Rating for Evolus (NASDAQ:EOLS) - MarketBeat
Midday Stock Roundup: NKGen Biotech Plummets 35% - Orange County Business Journal
Stonepine Capital Management LLC Sells 1,016,745 Shares of Evolus, Inc. (NASDAQ:EOLS) - Defense World
Evolus Inc.'s SWOT analysis: aesthetics stock poised for growth amid challenges - Investing.com UK
Midday Stock Roundup: STAAR Surgical CO. Shares Surge 22% - Orange County Business Journal
Armistice Capital LLC Acquires Shares of 360,000 Evolus, Inc. (NASDAQ:EOLS) - MarketBeat
Evolus Defeats Investor Suit Over Botox Trade Secret Dispute - Bloomberg Law
Great Point Partners LLC Has $26.60 Million Stock Holdings in Evolus, Inc. (NASDAQ:EOLS) - Defense World
Evolus Inc (EOLS) Shares Up 3.22% on Sep 20 - GuruFocus.com
Finanzdaten der Evolus Inc-Aktie (EOLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.88%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):